Cutting Edge: Engagement of CD40 Antigen with Soluble CD40 Ligand Up-Regulates Peptide Transporter Expression and Restores Endogenous Processing Function in Burkitt's Lymphoma Cells

Journal of Immunology

Volumn 159, Issue 12, 1997, Pages 5782-5785

  Khanna, Rajiv ^a   Cooper, Leanne ^a   Kienzle, Nobert ^a   Moss, Denis J ^a   Burrows, Scott R ^a   Khanna, Kum Kum ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CD40 ANTIGEN; CD40 LIGAND; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; LIGAND; MEMBRANE PROTEIN; TAP1 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; ARTICLE; BIOSYNTHESIS; BURKITT LYMPHOMA; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOLOGY; METABOLISM; SOLUBILITY; UPREGULATION; VIROLOGY;

ANTIGEN PRESENTATION; ANTIGENS, CD40; ATP-BINDING CASSETTE TRANSPORTERS; BURKITT LYMPHOMA; CD40 LIGAND; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; LIGANDS; MEMBRANE GLYCOPROTEINS; SOLUBILITY; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0031573606     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397.
2. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
3. + T cells by B7-transfected melanoma cells [see comments]. Science 259:368.
4. Anichini, A., G. Fossati, and G. Parmiani. 1986. Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones. J. Exp. Med. 163:215.
5. Khanna, R., S. R. Burrows, V. Argaet, and D. J. Moss. 1994. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int. Immunol. 6:639.
6. Rowe, M., R. Khanna, C. A. Jacob, V. Argaet, A. Kelly, S. Powis, M. Belich, D. Croom Carter, S. Lee, S. R. Burrows, D. J. Moss, and A. B. Rickinson. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1 : coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 25:1374.
7. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mule, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265.
8. Cromme, F. V., P. F. van Bommel, J. M. Walboomers, M. P. Gallee, P. L. Stern, P. Kenemans, T. J. Helmerhorst, M. J. Stukart, and C. J. Meijer. 1994. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br. J. Cancer 69:1176.
9. Seliger, B., A. Hohne, A. Knuth, H. Bernhard, T. Meyer, R. Tampe, F. Momburg, and C. Huber. 1996. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. 56: 1756.
10. Andersson, M. L., N. J. Stam, G. Klein, H. L. Ploegh, and M. G. Masucci. 1991. Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells. Int. J. Cancer 47:544.
11. Burrows, S. R., S. J. Rodda, A. Suhrbier, H. M. Geysen, and D. J. Moss. 1992. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur. J. Immunol. 22:191.
12. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169.
13. + EBV-specific CTL. J. Immunol. 157:3619.
14. Khanna, R., C. A. Jacob, S. R. Burrows, and D. J. Moss. 1993. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J. Immunol. Methods 164:41.
15. Moss, D. J., I. S. Misko, S. R. Burrows, K. Burman, R. McCarthy, and T. B. Sculley. 1988. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331:719.
16. van Endert, P. M., R. Tampe, T. H. Meyer, R. Tisch, J. F. Bach, and H. O. McDevitt. 1994. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity 1:491.
17. Khanna, R., C. A. Jacob, S. R. Burrows, M. G. Kurilla, E. Kieff, I. S. Misko, and D. J. Moss. 1991. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T-cells. Immunology 74:504.
18. Van den Hove, I. E., S. W. Van Gool, P. Vandenberghe, M. Bakkus, K. Thielemans, M. A. Boogaerts, and J. L. Ceuppens. 1997. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 co-stimulatory molecules. Leukemia 11:572.
19. Neumann, M., G. Wohlleben, S. Chuvpilo, B. Kistler, T. Wirth, E. Serfling, and A. Schimpl. 1996. CD40, but not lipopolysaccharide and anti-IgM stimulation of primary B lymphocytes, leads to a persistent nuclear accumulation of RelB. J. Immunol. 157:4862.